Skip to main content
Top
Published in: BMC Nephrology 1/2017

Open Access 01-12-2017 | Research article

Prevalence of chronic kidney disease in Peruvian primary care setting

Authors: Percy Herrera-Añazco, Alvaro Taype-Rondan, María Lazo-Porras, E. Alberto Quintanilla, Victor Manuel Ortiz-Soriano, Adrian V. Hernandez

Published in: BMC Nephrology | Issue 1/2017

Login to get access

Abstract

Background

Chronic Kidney Disease (CKD) is a worldwide public health problem. There are few studies in Latin America, especially in primary care settings. Our objective was to determine the prevalence, stages, and associated factors of CKD in primary care setting.

Methods

We did a retrospective secondary analysis of a database from the Diabetes and Hypertension Primary Care Center of the Peruvian Social Security System (EsSalud) in Lima, Peru. We defined CKD as the presence of eGFR <60 mL/min and/or albuminuria >30 mg/day in 24 h, according to Kidney Disease: Improving Global Outcomes (KDIGO). Factors associated with CKD were evaluated with Poisson Regression models; these factors included age, gender, type 2 diabetes mellitus (DM2), hypertension (HTN), body mass index (BMI), and uric acid. Associations were described as crude and adjusted prevalence ratios (PR) and their 95% confidence intervals (95% CI).

Results

We evaluated 1211 patients (women [59%], mean age 65.8 years [SD: 12.7]). Prevalence of CKD was 18%. Using the estimated glomerular filtration rate (eGFR), the prevalence was 9.3% (95% CI 5.3 – 13.3) in patients without HTN or DM2; 20.2% (95% CI 17.6 – 22.8) in patients with HTN, and 23.9% (95% CI 19.4 – 28.4) in patients with DM2. The most common stages were 1 and 2 with 41.5% and 48%, respectively. Factors associated with CKD in the adjusted analysis were: age in years (PR = 1.03, 95% CI 1.01 – 1.04), DM2 (PR = 3.37, 95% CI 1.09 – 10.39), HTN plus DM2 (PR = 3.90, 95% CI 1.54 – 9.88), and uric acid from 5 to <7 mg/dL (PR = 2.04, 95% CI 1.31 – 3.19) and ≥7 mg/dL (PR = 5.19, 95% CI 3.32 – 8.11).

Conclusions

Prevalence of CKD in the primary care setting population was high. CKD is more frequent in the early stages of the disease, and individuals with hypertension, DM2, older age and hyperuricemia have higher prevalence of CKD.
Appendix
Available only for authorised users
Literature
1.
go back to reference Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third National Health and nutrition examination survey. Am J Kidney Dis. 2003;41:1–12.CrossRefPubMed Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third National Health and nutrition examination survey. Am J Kidney Dis. 2003;41:1–12.CrossRefPubMed
2.
go back to reference Hallan SI, Coresh J, Astor BC, et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol. 2006;17:2275–84.CrossRefPubMed Hallan SI, Coresh J, Astor BC, et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol. 2006;17:2275–84.CrossRefPubMed
3.
go back to reference Hillege HL, Janssen WM, Bak AA, et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med. 2001;249:519–26.CrossRefPubMed Hillege HL, Janssen WM, Bak AA, et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med. 2001;249:519–26.CrossRefPubMed
4.
go back to reference Chadban SJ, Briganti EM, Kerr PG, Dunstan DW, Welborn TA, et al. Prevalence of kidney damage in Australian adults: the AusDiab kidney study. J Am Soc Nephrol. 2003;14(7 suppl 2):S131–8.CrossRefPubMed Chadban SJ, Briganti EM, Kerr PG, Dunstan DW, Welborn TA, et al. Prevalence of kidney damage in Australian adults: the AusDiab kidney study. J Am Soc Nephrol. 2003;14(7 suppl 2):S131–8.CrossRefPubMed
5.
go back to reference Mills KT, Xu Y, Zhang W, et al. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. Kidney Int. 2015;88:950–7.CrossRefPubMedPubMedCentral Mills KT, Xu Y, Zhang W, et al. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. Kidney Int. 2015;88:950–7.CrossRefPubMedPubMedCentral
6.
go back to reference Stanifern JW, Muiru A, Tazeen H. Jafar and Uptal D. Pate chronic kidney disease in low- and middle-income countries. Nephrol Dial Transplant. 2016;31:868–74.CrossRef Stanifern JW, Muiru A, Tazeen H. Jafar and Uptal D. Pate chronic kidney disease in low- and middle-income countries. Nephrol Dial Transplant. 2016;31:868–74.CrossRef
7.
go back to reference Obrador GT, Garcia-Garcia G, Villa AR, et al. Prevalence of chronic kidney disease in the kidney early evaluation program (KEEP) Mexico and comparison with KEEP US. Kidney Int Suppl. 2010;77:S2–8.CrossRef Obrador GT, Garcia-Garcia G, Villa AR, et al. Prevalence of chronic kidney disease in the kidney early evaluation program (KEEP) Mexico and comparison with KEEP US. Kidney Int Suppl. 2010;77:S2–8.CrossRef
8.
go back to reference Orantes CM, Herrera R, Almaguer M, Brizuela EG, Núñez L, et al. Epidemiology of chronic kidney disease in adults of Salvadoran agricultural communities. MEDICC Rev. 2014;16:23–30.PubMed Orantes CM, Herrera R, Almaguer M, Brizuela EG, Núñez L, et al. Epidemiology of chronic kidney disease in adults of Salvadoran agricultural communities. MEDICC Rev. 2014;16:23–30.PubMed
9.
go back to reference O’Donnell JK, Tobey M, Weiner DE, et al. Prevalence of and risk factors for chronic kidney disease in rural Nicaragua. Nephrol Dial Transplant. 2011;26:2798–805.CrossRefPubMed O’Donnell JK, Tobey M, Weiner DE, et al. Prevalence of and risk factors for chronic kidney disease in rural Nicaragua. Nephrol Dial Transplant. 2011;26:2798–805.CrossRefPubMed
10.
go back to reference Francis ER, Kuo CC, Bernabe-Ortiz A, Nessel L, Gilman RH, et al. Burden of chronic kidney disease in resource-limited settings from Peru: a population-based study. BMC Nephrol. 2015;16:114.CrossRefPubMedPubMedCentral Francis ER, Kuo CC, Bernabe-Ortiz A, Nessel L, Gilman RH, et al. Burden of chronic kidney disease in resource-limited settings from Peru: a population-based study. BMC Nephrol. 2015;16:114.CrossRefPubMedPubMedCentral
11.
go back to reference Stenvinkel P. Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. J Intern Med. 2010;268:456–67.CrossRefPubMed Stenvinkel P. Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. J Intern Med. 2010;268:456–67.CrossRefPubMed
13.
go back to reference Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015;385:1975–82.CrossRefPubMed Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015;385:1975–82.CrossRefPubMed
14.
go back to reference Sánchez-Moreno F. The national health system in Peru. Rev Peru Med Exp Salud Pública. 2014;31(4):747–53.PubMed Sánchez-Moreno F. The national health system in Peru. Rev Peru Med Exp Salud Pública. 2014;31(4):747–53.PubMed
15.
go back to reference Herrera-Añazco P, Benites-Zapata VA, León-Yurivilca I, Huarcaya-Cotaquispe R, Silveira-Chau M. Chronic kidney disease in Peru: a challenge for a country with an emerging economy. J Bras Nefrol. 2015;37(4):507–8.CrossRefPubMed Herrera-Añazco P, Benites-Zapata VA, León-Yurivilca I, Huarcaya-Cotaquispe R, Silveira-Chau M. Chronic kidney disease in Peru: a challenge for a country with an emerging economy. J Bras Nefrol. 2015;37(4):507–8.CrossRefPubMed
16.
go back to reference Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014;63(5):713–35.CrossRefPubMed Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014;63(5):713–35.CrossRefPubMed
18.
go back to reference Hill NR, Fatoba ST, Oke JL, Hirst JA, O'Callaghan CA, et al. Global prevalence of chronic kidney disease – a systematic review and meta-analysis. PLoS One. 2016;11(7):e0158765.CrossRefPubMedPubMedCentral Hill NR, Fatoba ST, Oke JL, Hirst JA, O'Callaghan CA, et al. Global prevalence of chronic kidney disease – a systematic review and meta-analysis. PLoS One. 2016;11(7):e0158765.CrossRefPubMedPubMedCentral
19.
go back to reference Elsharif ME, Abdullha SM, Abdalla SM, Allaelsharif EG. The magnitude of chronic kidney diseases among primary health care attendees in Gezira state, Sudan. Saudi J Kidney Dis Transpl. 2013;24(4):807–9.CrossRefPubMed Elsharif ME, Abdullha SM, Abdalla SM, Allaelsharif EG. The magnitude of chronic kidney diseases among primary health care attendees in Gezira state, Sudan. Saudi J Kidney Dis Transpl. 2013;24(4):807–9.CrossRefPubMed
20.
go back to reference Zúñiga SMC, Müller OH, Flores OM. Prevalence of chronic kidney disease in subjects consulting in urban primary care clinics. Rev Med Chil. 2011;139(9):1176–84.CrossRef Zúñiga SMC, Müller OH, Flores OM. Prevalence of chronic kidney disease in subjects consulting in urban primary care clinics. Rev Med Chil. 2011;139(9):1176–84.CrossRef
21.
go back to reference De Nicola L, Zoccali C. Chronic kidney disease prevalence in the general population: heterogeneity and concerns. Nephrol Dial Transplant. 2016;31(3):331–5.CrossRefPubMed De Nicola L, Zoccali C. Chronic kidney disease prevalence in the general population: heterogeneity and concerns. Nephrol Dial Transplant. 2016;31(3):331–5.CrossRefPubMed
22.
go back to reference Jafar TH, Schmid CH, Levey AS. Serum creatinine as marker of kidney function in south Asians: a study of reduced GFR in adults in Pakistan. J Am Soc Nephrol. 2005;16:1413–9.CrossRefPubMed Jafar TH, Schmid CH, Levey AS. Serum creatinine as marker of kidney function in south Asians: a study of reduced GFR in adults in Pakistan. J Am Soc Nephrol. 2005;16:1413–9.CrossRefPubMed
23.
go back to reference Anand S, Khanam MA, Saquib J, et al. High prevalence of chronic kidney disease in a community survey of urban Bangladeshis: a cross-sectional study. Glob Health. 2014;10:9.CrossRef Anand S, Khanam MA, Saquib J, et al. High prevalence of chronic kidney disease in a community survey of urban Bangladeshis: a cross-sectional study. Glob Health. 2014;10:9.CrossRef
24.
go back to reference Silva LC, Ordúñez P. Chronic kidney disease in central American agricultural communities: challenges for epidemiology and public health. MEDICC Rev. 2014;16(2):66–71.PubMed Silva LC, Ordúñez P. Chronic kidney disease in central American agricultural communities: challenges for epidemiology and public health. MEDICC Rev. 2014;16(2):66–71.PubMed
25.
go back to reference Shardlow A, McIntyre NJ, Fluck RJ, et al. Chronic kidney disease in primary care: outcomes after five years in a prospective cohort study. PLoS Med. 2016;13:e1002128.CrossRefPubMedPubMedCentral Shardlow A, McIntyre NJ, Fluck RJ, et al. Chronic kidney disease in primary care: outcomes after five years in a prospective cohort study. PLoS Med. 2016;13:e1002128.CrossRefPubMedPubMedCentral
26.
go back to reference Tomonaga Y, Risch L, Szucs TD, Ambühl PM. The prevalence of chronic kidney disease in a primary care setting: a Swiss cross-sectional study. PLoS One. 2013;8(7):e67848.CrossRefPubMedPubMedCentral Tomonaga Y, Risch L, Szucs TD, Ambühl PM. The prevalence of chronic kidney disease in a primary care setting: a Swiss cross-sectional study. PLoS One. 2013;8(7):e67848.CrossRefPubMedPubMedCentral
27.
go back to reference Herrera-Añazco P, Benites-Zapata V, Hernandez AV, Mezones-Holguin E, Silveira-Chau M. Mortality in patients with chronic kidney disease undergoing hemodialysis in a public hospital of Peru. J Bras Nefrol. 2015;37(2):192–7.CrossRefPubMed Herrera-Añazco P, Benites-Zapata V, Hernandez AV, Mezones-Holguin E, Silveira-Chau M. Mortality in patients with chronic kidney disease undergoing hemodialysis in a public hospital of Peru. J Bras Nefrol. 2015;37(2):192–7.CrossRefPubMed
28.
29.
go back to reference Salvador González B, Rodríguez Pascual M, Ruipérez Guijarro L, Ferré González A, Cunillera Puertolas O, et al. Enfermedad renal crónica en Atención Primaria: prevalencia y factores de riesgo asociados. Aten Primaria. 2015;47(4):236–45.CrossRefPubMed Salvador González B, Rodríguez Pascual M, Ruipérez Guijarro L, Ferré González A, Cunillera Puertolas O, et al. Enfermedad renal crónica en Atención Primaria: prevalencia y factores de riesgo asociados. Aten Primaria. 2015;47(4):236–45.CrossRefPubMed
30.
go back to reference Bernabe-Ortiz A, Sanchez JF, Carrillo-Larco RM, Gilman RH, Poterico JA, et al. Rural-to-urban migration and risk of hypertension: longitudinal results of the PERU MIGRANT study. J Hum Hypertens. 2017;31(1):22–8.CrossRefPubMed Bernabe-Ortiz A, Sanchez JF, Carrillo-Larco RM, Gilman RH, Poterico JA, et al. Rural-to-urban migration and risk of hypertension: longitudinal results of the PERU MIGRANT study. J Hum Hypertens. 2017;31(1):22–8.CrossRefPubMed
31.
go back to reference Herrera-Añazco P. V Hernandez a. Mezones Holguin E. Diabetes mellitus and diabetic nephropathy in peru. Nefrología, Diálisis y Trasplante. 2015;35(4):229–37. Herrera-Añazco P. V Hernandez a. Mezones Holguin E. Diabetes mellitus and diabetic nephropathy in peru. Nefrología, Diálisis y Trasplante. 2015;35(4):229–37.
32.
go back to reference Chang A, Kramer H. CKD progression: a risky business. Nephrol Dial Transplant. 2012;27(7):2607–9.CrossRefPubMed Chang A, Kramer H. CKD progression: a risky business. Nephrol Dial Transplant. 2012;27(7):2607–9.CrossRefPubMed
33.
go back to reference Carrillo-Larco RM, Bernabé-Ortiz A, Pillay TD, Gilman RH, Sanchez JF, et al. Obesity risk in rural, urban and rural-to-urban migrants: prospective results of the PERU MIGRANT study. Int J Obes. 2016;40(1):181–5.CrossRef Carrillo-Larco RM, Bernabé-Ortiz A, Pillay TD, Gilman RH, Sanchez JF, et al. Obesity risk in rural, urban and rural-to-urban migrants: prospective results of the PERU MIGRANT study. Int J Obes. 2016;40(1):181–5.CrossRef
34.
go back to reference Zhu P, Liu Y, Han L, Xu G, Ran JM. Serum uric acid is associated with incident chronic kidney disease in middle-aged populations: a meta-analysis of 15 cohort studies. PLoS One. 2014;9(6):e100801.CrossRefPubMedPubMedCentral Zhu P, Liu Y, Han L, Xu G, Ran JM. Serum uric acid is associated with incident chronic kidney disease in middle-aged populations: a meta-analysis of 15 cohort studies. PLoS One. 2014;9(6):e100801.CrossRefPubMedPubMedCentral
36.
go back to reference Kodama S, Saito K, Yachi Y, Asumi M, Sugawara A, et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care. 2009;32(9):1737–42.CrossRefPubMedPubMedCentral Kodama S, Saito K, Yachi Y, Asumi M, Sugawara A, et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care. 2009;32(9):1737–42.CrossRefPubMedPubMedCentral
37.
go back to reference Miranda JJ, Herrera VM, Chirinos JA, Gómez LF, Perel P, Pichardo R, et al. Major cardiovascular risk factors in Latin America: a comparison with the United States. The Latin American consortium of studies in obesity (LASO). PLoS One. 2013;8(1):e54056.CrossRefPubMedPubMedCentral Miranda JJ, Herrera VM, Chirinos JA, Gómez LF, Perel P, Pichardo R, et al. Major cardiovascular risk factors in Latin America: a comparison with the United States. The Latin American consortium of studies in obesity (LASO). PLoS One. 2013;8(1):e54056.CrossRefPubMedPubMedCentral
38.
go back to reference Pérez-Loredo J, Lavorato CA. A Negri AL, measured and estimated glomerular filtration rate. Numerous methods of measurements (PART 1). Nefrología, Diálisis y Trasplante. 2015;35(3):153–64. Pérez-Loredo J, Lavorato CA. A Negri AL, measured and estimated glomerular filtration rate. Numerous methods of measurements (PART 1). Nefrología, Diálisis y Trasplante. 2015;35(3):153–64.
39.
go back to reference Brück K, Jager KJ, Dounousi E, Kainz A, Nitsch D, et al. Methodology used in studies reporting chronic kidney disease prevalence: a systematic literature review. Nephrol Dial Transplant. 2015;30(Suppl 4):iv6–16.CrossRefPubMedPubMedCentral Brück K, Jager KJ, Dounousi E, Kainz A, Nitsch D, et al. Methodology used in studies reporting chronic kidney disease prevalence: a systematic literature review. Nephrol Dial Transplant. 2015;30(Suppl 4):iv6–16.CrossRefPubMedPubMedCentral
40.
go back to reference Glassock RJ, Warnock DG, Delanaye P. The global burden of chronic kidney disease: estimates, variability and pitfalls. Nat Rev Nephrol. 2017;13(2):104–14.CrossRefPubMed Glassock RJ, Warnock DG, Delanaye P. The global burden of chronic kidney disease: estimates, variability and pitfalls. Nat Rev Nephrol. 2017;13(2):104–14.CrossRefPubMed
Metadata
Title
Prevalence of chronic kidney disease in Peruvian primary care setting
Authors
Percy Herrera-Añazco
Alvaro Taype-Rondan
María Lazo-Porras
E. Alberto Quintanilla
Victor Manuel Ortiz-Soriano
Adrian V. Hernandez
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2017
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-017-0655-x

Other articles of this Issue 1/2017

BMC Nephrology 1/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.